How can probiotic improve irritable bowel syndrome symptoms?
| Autor: | Goran Hauser, Indira Benjak Horvat, Ivana Gobin, Andrea Kresović |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Abdominal pain
medicine.medical_specialty Combination therapy medicine.medical_treatment Prebiotic Review Symbiotic Gut flora Probiotic law.invention Bloating law Internal medicine medicine BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine Irritable bowel syndrome BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina biology business.industry Microbiota medicine.disease biology.organism_classification Diarrhoea Surgery Clinical trial Obstipation Irritable bowel syndrome Obstipation Diarrhoea Abdominal pain Probiotic Prebiotic Symbiotic Microbiota medicine.symptom business |
| Zdroj: | World Journal of Gastrointestinal Surgery Volume 13 Issue 9 |
| ISSN: | 1948-9366 |
| Popis: | The onset and manifestations of irritable bowel syndrome (IBS) is associated with several factors, and the pathophysiology involves various central and peripheral mechanisms. Most studies indicate that the management of gut microbiota could significantly affect the improvement of subjective disorders in patients with IBS. Numerous clinical trials have assessed the efficacy of probiotics for IBS with controversial conclusions. Several clinical trials have suggested that probiotics can improve global IBS symptoms, while others only improve individual IBS symptoms, such as bloating scores and abdominal pain scores. Only a few clinical trials have found no apparent effect of probiotics on IBS symptoms. Generally, probiotics appear to be safe for patients with IBS. However, the question of which probiotics should be used for certain IBS subtypes remains unresolved. In everyday practice, the dose of the recommended probiotic remains questionable, as well as how long the probiotic should be used in therapy. The use of probiotics in the M subtype and non- classified IBS is particularly problematic, in which combination therapy should be recommended due to the change in symptoms. Therefore, new approaches are needed in the design of clinical studies that should address certain subtypes of IBS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|